Você procurou por: streptokinase (Inglês - Maltês)

treated with a non-fibrin specific agent (primarily streptokinase).
mill-pazjenti trattati b’sustanza trombolitika, 84% ħadu trattament b’aġent mhux speċifiku għal-fibrin (primarjament streptokinase).

concomitant treatment with thrombolytics (e.g. rt-pa or streptokinase) may
kura flimkien ma’ trombolitiċi (e.ż. rt-pa jew streptokinase) jistgħu

19 treated with a non-fibrin specific agent (primarily streptokinase).
streptokinase).

medicines used to break down blood clots (e.g. alteplase and streptokinase).
mediċini użati biex iħollu l-emboli tad-demm (eż. alteplase u streptokinase).

eptifibatide appeared to increase the risk of bleeding when administered with streptokinase in an acute myocardial infarction study.
fi studju dwar infart mijokardijaku akut, eptifibatide deher li jżid ir-riskju ta’ fsada meta jkun mogħti flimkien ma’ streptokinase.

rapilysin was more effective than streptokinase in reducing the number of patients with heart failure, and it was as effective as streptokinase in preventing death.
rapilysin kien aktar effettiv minn streptokinase fit-tnaqqis tal-għadd ta' pazjenti b'insuffiċjenza kardijaka, u kien effettiv daqs streptokinase fil-prevenzjoni ta' mewt.

rapilysin has been compared with other medicines used to dissolve blood clots: streptokinase in 6,000 patients and alteplase in about 15,000 patients.
rapilysin tqabbel ma' mediċini oħra li jintużaw biex iħollu l-emboli tad-demm: streptokinase f'6,000 pazjent u alteplase f'madwar 15,000 pazjent.

of the patients treated with a thrombolytic, 84% were treated with a non-fibrin specific agent (primarily streptokinase).
mill-pazjenti trattati b’sustanza trombolitika, 84% ħadu trattament b’aġent mhux speċifiku għal-fibrin (primarjament streptokinase).

also tell your doctor that because you are taking brilique, you may have an increased risk of bleeding if your doctor gives you fibrinolytics, often called ‘clot dissolvers’, such as streptokinase or alteplase.
għid lit-tabib tiegħek ukoll li minħabba li qed tieħu brilique, jista’ jkollok żieda fir-riskju ta’ fsada jekk it-tabib tiegħek jagħtik fibrinolitiċi magħrufa bħala dawk li jħollu d-demm magħqud li jinkludu streptokinase u alteplase.